Fumiichiro and Miyako examined the genes change, found that up‐regulation of ESCO2 was striking in breast cancer tissues and cell lines.9 Notably, the dysregulated ESCO2 was implicated to adjust metastatic activity in colorectal cancer (CRC), suppressing Matrix Metallopeptidase 2 (MMP2).10 Yet, whether and how the progression of RCC is controlled by ESCO2 has not been resolved. The gene discussed is MMP2; the disease is breast carcinoma.